PL2394664T3 - Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu - Google Patents

Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu

Info

Publication number
PL2394664T3
PL2394664T3 PL10382154.2T PL10382154T PL2394664T3 PL 2394664 T3 PL2394664 T3 PL 2394664T3 PL 10382154 T PL10382154 T PL 10382154T PL 2394664 T3 PL2394664 T3 PL 2394664T3
Authority
PL
Poland
Prior art keywords
injectable depot
depot composition
antipsychotic
antipsychotic injectable
composition
Prior art date
Application number
PL10382154.2T
Other languages
English (en)
Inventor
Aduriz Ibon Gutierro
Ochoa María Teresa Gomez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43301889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2394664(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL2394664T3 publication Critical patent/PL2394664T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
PL10382154.2T 2010-05-31 2010-05-31 Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu PL2394664T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382154.2A EP2394664B1 (en) 2010-05-31 2010-05-31 Antipsychotic injectable depot composition

Publications (1)

Publication Number Publication Date
PL2394664T3 true PL2394664T3 (pl) 2016-12-30

Family

ID=43301889

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10382154.2T PL2394664T3 (pl) 2010-05-31 2010-05-31 Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu
PL11725383.1T PL2575890T3 (pl) 2010-05-31 2011-05-31 Kompozycja przeciwpsychotyczna do wstrzykiwań w postaci depot

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11725383.1T PL2575890T3 (pl) 2010-05-31 2011-05-31 Kompozycja przeciwpsychotyczna do wstrzykiwań w postaci depot

Country Status (33)

Country Link
US (2) US10085936B2 (pl)
EP (2) EP2394664B1 (pl)
JP (1) JP5882993B2 (pl)
KR (1) KR101784330B1 (pl)
CN (1) CN103002917B (pl)
AP (1) AP3524A (pl)
AU (1) AU2011260318B2 (pl)
BR (1) BR112012030686B1 (pl)
CA (1) CA2800111C (pl)
CL (1) CL2012003350A1 (pl)
CY (2) CY1117964T1 (pl)
DK (2) DK2394664T3 (pl)
EA (1) EA024155B1 (pl)
ES (2) ES2589106T3 (pl)
HR (2) HRP20161049T1 (pl)
HU (2) HUE029895T2 (pl)
IL (1) IL223129A (pl)
LT (2) LT2394664T (pl)
MA (1) MA34296B1 (pl)
ME (1) ME02501B (pl)
MX (1) MX338373B (pl)
MY (1) MY161930A (pl)
NZ (1) NZ604342A (pl)
PH (1) PH12012502338B1 (pl)
PL (2) PL2394664T3 (pl)
PT (2) PT2394664T (pl)
RS (1) RS55190B1 (pl)
SG (1) SG185775A1 (pl)
SI (2) SI2394664T1 (pl)
SM (2) SMT201600321B (pl)
UA (1) UA108885C2 (pl)
WO (1) WO2011151355A1 (pl)
ZA (1) ZA201209346B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2008153611A2 (en) 2007-05-25 2008-12-18 Qlt Usa, Inc. Sustained delivery formulations of risperidone compounds
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
HUE057236T2 (hu) 2010-05-31 2022-04-28 Farm Rovi Lab Sa Készítmények befecskendezhetõ in-situ biológiailag lebontható implantátumokhoz
PT2394664T (pt) 2010-05-31 2016-09-06 Farm Rovi Lab Sa Composição depot para injetável antipsicótico
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
ES2456917T3 (es) * 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona
DK2529756T3 (da) * 2011-05-31 2021-08-02 Farm Rovi Lab Sa Risperidon- og/eller paliperidon-implantatformulering
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
JP2016512523A (ja) 2013-03-11 2016-04-28 デュレクト コーポレーション 高粘性液体キャリアを含む注射用制御放出組成物
WO2016199170A2 (en) * 2015-06-10 2016-12-15 Cipla Limited Paliperidone palmitate particles and compositions thereof
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
CN110420212A (zh) * 2019-08-19 2019-11-08 韩自勤 一种用于治疗精神分裂症组合物及其制备方法
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
CN119072314A (zh) 2022-05-18 2024-12-03 罗维实验室制药股份公司 用于利培酮与cyp2d6酶抑制剂联合治疗的缓释注射组合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE758156R (fr) 1970-05-13 1971-04-28 Ethicon Inc Element de suture absorbable et sa
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4523591A (en) 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5620700A (en) 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
SK282231B6 (sk) 1993-11-19 2001-12-03 Janssen Pharmaceutica N. V. Farmaceutický prostriedok na liečenie psychotických porúch
DE69705746T2 (de) 1996-12-20 2001-10-31 Alza Corp., Palo Alto Injizierbare depotgelzubereitung und herstellungsverfahren
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6331317B1 (en) * 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
DE10190041D2 (de) * 2000-01-11 2002-12-05 Roland Bodmeier Implantate, Partikel
US6604561B2 (en) * 2000-02-11 2003-08-12 Medical Instill Technologies, Inc. Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial
EP2030611A1 (en) * 2002-07-31 2009-03-04 Alza Corporation Injectable multimodal polymer depot compositions and uses thereof
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US20050003007A1 (en) 2003-07-02 2005-01-06 Michele Boix Method of sterilization of polymeric microparticles
DK1660039T3 (en) * 2003-07-18 2017-01-16 Oakwood Laboratories L L C PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
DE102005031868A1 (de) * 2005-07-04 2007-01-18 Biotronik Vi Patent Ag Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
FR2908775B1 (fr) * 2006-11-17 2012-08-31 Biomatlante Hydrogel et ses applications biomedicales
DK3202814T3 (da) 2007-02-15 2019-11-25 Tolmar Therapeutics Inc Poly-(laktid/glykolid) med lav udskilning og fremgangsmåder til at fremstille polymerer
US20080287464A1 (en) * 2007-05-18 2008-11-20 Wright Jeremy C Depot Formulations
WO2008153611A2 (en) 2007-05-25 2008-12-18 Qlt Usa, Inc. Sustained delivery formulations of risperidone compounds
AR070033A1 (es) * 2007-11-06 2010-03-10 Panacea Biotec Ltd Composiciones inyectables, sus procesos y usos
MX347056B (es) * 2008-08-12 2017-04-10 Novartis Ag Composiciones farmaceuticas.
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
PT2394664T (pt) 2010-05-31 2016-09-06 Farm Rovi Lab Sa Composição depot para injetável antipsicótico
HUE057236T2 (hu) 2010-05-31 2022-04-28 Farm Rovi Lab Sa Készítmények befecskendezhetõ in-situ biológiailag lebontható implantátumokhoz
DK2529756T3 (da) 2011-05-31 2021-08-02 Farm Rovi Lab Sa Risperidon- og/eller paliperidon-implantatformulering
ES2456917T3 (es) 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona

Also Published As

Publication number Publication date
KR101784330B1 (ko) 2017-10-11
EA024155B1 (ru) 2016-08-31
AU2011260318A1 (en) 2013-01-10
CA2800111C (en) 2018-05-22
ZA201209346B (en) 2013-08-28
SMT201600321B (it) 2016-11-10
CY1117964T1 (el) 2017-05-17
RS55190B1 (sr) 2017-01-31
IL223129A0 (en) 2013-02-03
LT2575890T (lt) 2016-09-26
US10085936B2 (en) 2018-10-02
AU2011260318B2 (en) 2014-11-27
SI2575890T1 (sl) 2016-10-28
UA108885C2 (uk) 2015-06-25
KR20130118742A (ko) 2013-10-30
MX338373B (es) 2016-04-13
EP2575890B1 (en) 2016-06-01
CA2800111A1 (en) 2011-12-08
ES2589106T3 (es) 2016-11-10
PT2394664T (pt) 2016-09-06
SI2394664T1 (sl) 2016-10-28
JP2013528612A (ja) 2013-07-11
HRP20161100T1 (hr) 2016-11-04
AP2012006626A0 (en) 2012-12-31
BR112012030686B1 (pt) 2022-11-01
DK2575890T3 (en) 2016-09-12
MA34296B1 (fr) 2013-06-01
US20180221272A1 (en) 2018-08-09
HRP20161049T1 (hr) 2016-12-30
EP2394664B1 (en) 2016-06-01
JP5882993B2 (ja) 2016-03-09
SMT201600320B (it) 2016-11-10
CY1117969T1 (el) 2017-05-17
MX2012013937A (es) 2013-02-11
EP2394664A1 (en) 2011-12-14
WO2011151355A1 (en) 2011-12-08
SG185775A1 (en) 2013-01-30
IL223129A (en) 2016-02-29
ME02501B (me) 2017-02-20
PH12012502338A1 (en) 2013-02-11
HUE029056T2 (en) 2017-02-28
CL2012003350A1 (es) 2013-10-18
MY161930A (en) 2017-05-15
PT2575890T (pt) 2016-09-06
US10182982B2 (en) 2019-01-22
US20130171202A1 (en) 2013-07-04
PL2575890T3 (pl) 2016-12-30
ES2592527T3 (es) 2016-11-30
EA201201569A1 (ru) 2013-04-30
DK2394664T3 (en) 2016-09-12
PH12012502338B1 (en) 2018-08-31
BR112012030686A2 (pt) 2020-08-25
LT2394664T (lt) 2016-09-26
NZ604342A (en) 2014-11-28
CN103002917B (zh) 2016-04-27
CN103002917A (zh) 2013-03-27
EP2575890A1 (en) 2013-04-10
HUE029895T2 (en) 2017-04-28
AP3524A (en) 2016-01-11

Similar Documents

Publication Publication Date Title
AP3524A (en) Antipsychotic injectable depot composition
IL254417A0 (en) A flowable, injectable preparation containing buprenorphine
GB201002983D0 (en) Nutritinal composition
GB201006200D0 (en) Composition
PL2550243T3 (pl) Kompozycja ogniotrwała
GB201006178D0 (en) Composition
IL206739A0 (en) Injectable pharmaceutical composition
GB201007531D0 (en) Composition
GB201006214D0 (en) Composition
GB201006204D0 (en) Composition
GB201004717D0 (en) Composition
GB201010657D0 (en) Composition
GB201006175D0 (en) Composition
GB201006182D0 (en) Composition
GB201006012D0 (en) Composition
GB201002356D0 (en) Composition
IL199679A0 (en) Injectable pharmaceutical composition
GB201003768D0 (en) Composition
GB201005377D0 (en) Composition
GB201003347D0 (en) Tppical composition
GB201006215D0 (en) Composition
GB201006181D0 (en) Composition
GB201000147D0 (en) Imageble composition
GB201008259D0 (en) Composition
GB201009699D0 (en) Composition